PMID- 16495007
OWN - NLM
STAT- MEDLINE
DCOM- 20060622
LR  - 20210112
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 121
IP  - 3
DP  - 2006 Apr
TI  - Analgesia and hyperalgesia from CRF receptor modulation in the central nervous 
      system of Fischer and Lewis rats.
PG  - 241-260
LID - 10.1016/j.pain.2005.12.024 [doi]
AB  - This study examines the contribution of central corticotropin-releasing factor 
      (CRF) to pain behavior. CRF is the principal modulator of the 
      hypothalamo-pituitary-adrenal (HPA) axis, in addition to acting on many other 
      areas of the central nervous system. We compared nociceptive thresholds (heat and 
      mechanical) and pain behavior in response to a sustained stimulus (formalin test) 
      between Fischer and Lewis rats that have different HPA axis activity. 
      Intracerebroventricular (i.c.v.) administration of CRF produced dose-dependent 
      antinociception at a lower dose in Lewis (40 ng, paw pinch 71+/-0 g) compared to 
      Fischer rats (200 ng, 112+/-3 g). The antinociceptive effect of CRF was mostly 
      preserved in adrenalectomized Fischer rats. The i.c.v. administration of the CRF 
      receptor antagonist, astressin, had a hyperalgesic effect, suggesting that CRF is 
      tonically active. Lewis rats required higher doses of astressin (5 ng, paw pinch 
      51+/-1 g) to show nociceptive effects compared to Fischer rats (1 ng, 79+/-1 g). 
      Only Lewis rats vocalized during mechanical stimulus, and this behavior was 
      prevented by diazepam or morphine but was worsened by CRF, despite its 
      antinociceptive property. In the formalin test, CRF and astressin had the largest 
      effect on the interphase suggesting that they act on the endogenous pain 
      inhibitory system. CRF also increased anxiety/fear-like behaviors in the forced 
      swim and predator odor tests. Our results establish that central CRF is a key 
      modulator of pain behavior and indicates that CRF effects on nociception are 
      largely independent of its mood modulating effect as well as its control of the 
      HPA axis.
FAU - Vit, Jean-Philippe
AU  - Vit JP
AD  - Department of Neurological Surgery and the W.M. Keck Foundation Center for 
      Integrative Neuroscience, University of California San Francisco, San Francisco, 
      CA 94143, USA Department of Anatomy and the W.M. Keck Foundation Center for 
      Integrative Neuroscience, University of California San Francisco, San Francisco, 
      CA 94143, USA Department of Internal Medicine, Division of Rheumatology, 
      University of Michigan Health System, Ann Arbor, MI 48109-0723, USA.
FAU - Clauw, Daniel J
AU  - Clauw DJ
FAU - Moallem, Theodore
AU  - Moallem T
FAU - Boudah, Abdenasser
AU  - Boudah A
FAU - Ohara, Peter T
AU  - Ohara PT
FAU - Jasmin, Luc
AU  - Jasmin L
LA  - eng
GR  - R01 NS39320/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20060221
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Analgesics)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Corticotropin-Releasing Hormone)
RN  - 170809-51-5 (astressin)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
SB  - IM
MH  - Adrenalectomy
MH  - Analgesics/*metabolism/pharmacology
MH  - Animals
MH  - Anxiety/chemically induced/metabolism
MH  - Corticotropin-Releasing Hormone/adverse effects/*metabolism/pharmacology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Fear/drug effects/physiology
MH  - Female
MH  - Hyperalgesia/*metabolism/physiopathology
MH  - Hypothalamo-Hypophyseal System/drug effects/*metabolism
MH  - Injections, Intraventricular
MH  - Neuroprotective Agents/adverse effects
MH  - Pain/*metabolism/physiopathology
MH  - Pain Measurement/drug effects
MH  - Peptide Fragments/adverse effects
MH  - Pituitary-Adrenal System/drug effects/*metabolism
MH  - Rats
MH  - Rats, Inbred F344
MH  - Rats, Inbred Lew
MH  - Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors/metabolism
MH  - Vocalization, Animal/drug effects/physiology
EDAT- 2006/02/24 09:00
MHDA- 2006/06/23 09:00
CRDT- 2006/02/24 09:00
PHST- 2005/05/09 00:00 [received]
PHST- 2005/12/22 00:00 [revised]
PHST- 2005/12/22 00:00 [accepted]
PHST- 2006/02/24 09:00 [pubmed]
PHST- 2006/06/23 09:00 [medline]
PHST- 2006/02/24 09:00 [entrez]
AID - 00006396-200604000-00010 [pii]
AID - 10.1016/j.pain.2005.12.024 [doi]
PST - ppublish
SO  - Pain. 2006 Apr;121(3):241-260. doi: 10.1016/j.pain.2005.12.024. Epub 2006 Feb 21.